MELBOURNE, Australia--(BUSINESS WIRE)--Australian biotechnology company Avexa (ASX:AVX) today announced that it has completed recruitment of the first 160 patients for the two-dose component of its Phase III trial for apricitabine (ATC), with over 300 patients in the screening or dosing stages of the trial. The trial is ongoing with over 130 specialist HIV centres in 15 countries and results from this component of the trial are expected in the second quarter of 2009.
